证券代码：301263 证券简称：泰恩康 公告编号：2025-056 广东泰恩康医药股份有限公司 第五届监事会第十次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 广东泰恩康医药股份有限公司（以下简称"公司"）第五届监事会第十次会议 （以下简称"会议"）通知于 2025 年 8 月 9 日以电子邮件及书面送达方式向全体 监事发出，会议于 2025 年 8 月 19 日在公司会议室以通讯表决方式召开。会议由 监事会主席林姿丽女士召集主持，应出席监事 3 人，实际出席监事 3 人。 本次监事会会议召集、召开符合《中华人民共和国公司法》和《公司章程》 等的规定，会议决议合法、有效。 二、监事会会议审议情况 经与会监事充分讨论，本次会议审议通过议案如下： （一）审议通过《关于公司〈2025 年半年度报告〉及其摘要的议案》 监事会在全面审核公司《2025 年半年度报告》及其摘要后，认为：《2025 年 半年度报告》和《2025 年半年度报告摘要》的编制和审核程序符合相关法律法规， 报告内容真实、准确、完整地反映了公司 2025 年半年 ...

证券代码：301263 证券简称：泰恩康 公告编号：2025-059 广东泰恩康医药股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 特别提示： 一、会议召开和出席情况 （一）会议召开时间： （1）通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 8 月 20 日 9:15-9:25，9:30-11:30，13:00-15:00； （2）通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 8 月 （二）召开地点：广东省汕头市龙湖区泰山北路万吉南二街 8 号 A 幢三楼 会议室。 （三）召开方式：采取现场投票与网络投票相结合。 网络投票：广东泰恩康医药股份有限公司（以下简称"公司"）通过深圳证券 交易所交易系统和互联网投票系统向股东提供网络形式的投票平台。 （四）召集人：董事会 （五）主持人：董事长郑汉杰先生 （六）本次会议的召集、召开与表决程序符合《中华人民共和国公司法》 $$\mathbb{C}$$ 市公司股东会规则》等法律、法规、规范性文件以及《公司章程》《股东大会议 事规则》的规定。 （七）会议出席情况 通过现场和网 ...

Group 1 - The legal opinion letter confirms the legitimacy of the 2025 First Extraordinary General Meeting of Guangdong Tai'enkang Pharmaceutical Co., Ltd. [1][3] - The meeting was convened on August 20, 2025, following the approval of the board of directors on August 4, 2025, with proper notification to shareholders [2][3] - A total of 227 participants attended the meeting, representing 42,134,395 shares, which is 9.9488% of the total shares as of the record date [3][4] Group 2 - The meeting was chaired by Chairman Zheng Hanjie, and the procedures followed were in accordance with the Company Law and relevant regulations [3][5] - Voting was conducted through both on-site and online methods, with results announced immediately after the voting process [5][6] - The resolutions passed included significant support from shareholders, with over 99.9% approval for key proposals [6][7] Group 3 - The legal opinion concludes that the meeting's convening, procedures, and voting were all compliant with applicable laws and the company's articles of association, rendering the resolutions valid [7][8] - The legal opinion letter is to be submitted alongside other disclosure materials related to the meeting [7][9]

Meeting Announcement - The company will hold its second extraordinary general meeting of shareholders on September 10, 2025, as approved by the board of directors on August 19, 2025 [2][3] - The meeting will take place at 15:00 local time, with network voting available from 9:15 to 11:30 on the same day [2][3] Voting Procedures - Shareholders can choose between on-site voting and network voting, but must select only one method [3][4] - All ordinary shareholders registered by the close of trading on the registration date are entitled to attend and vote at the meeting [3][4] Agenda Items - The meeting will discuss proposals including the establishment and revision of internal control management systems and a management method to prevent the controlling shareholder and related parties from occupying company funds [3][4][11] Registration Details - Registration for corporate shareholders requires documentation including a business license copy and a representative's ID, while individual shareholders must present their shareholding proof and ID [5][6] - Registration for on-site attendance will occur on September 5, 2025, from 9:00 to 11:00 and 14:30 to 17:00 [5][6] Network Voting Instructions - The company provides a network voting platform through the Shenzhen Stock Exchange, with specific procedures outlined for participation [6][7]

泰恩康8月20日披露半年报，公司上半年实现营业收入3.47亿元，同比下降12.23%；归属于上市公司股 东的净利润3708.48万元，同比下降56.75%；基本每股收益0.09元。 ...

（文章来源：证券日报） 证券日报网讯 8月20日晚间，泰恩康发布公告称，2025年上半年公司实现营业收入347，080，567.60 元；归属于上市公司股东的净利润37，084，798.56元。 ...

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its operational performance [1] Financial Performance - The company achieved operating revenue of 347 million yuan, a year-on-year decrease of 12.23% [1] - The net profit attributable to shareholders was 37.08 million yuan, reflecting a year-on-year decline of 56.75% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 36.88 million yuan, down 56.30% year-on-year [1] - Basic earnings per share were reported at 0.09 yuan [1]

Core Insights - The company, 泰恩康, reported a decline in revenue and net profit for the first half of 2025, with revenue at 347 million yuan, down 12.23% year-on-year, and net profit at 37.08 million yuan, down 56.75% [1] Revenue Breakdown - The core segment of gastrointestinal medications saw a revenue increase of 103.39 million yuan, reflecting a year-on-year growth of 11.04% [1] - Revenue from ophthalmic medications was 79.38 million yuan, showing a decrease of 9.02% year-on-year [1] - The revenue from sexual health medications dropped significantly to 66.74 million yuan, a decline of 48.75% year-on-year, attributed to increased competition and a rise in the number of competing products [1]

Core Viewpoint - The company, 泰恩康 (301263.SZ), reported a decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance [1] Financial Performance - The company achieved an operating revenue of 347 million yuan, representing a year-on-year decrease of 12.23% [1] - The net profit attributable to shareholders of the listed company was 37.08 million yuan, down 56.75% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 36.88 million yuan, reflecting a year-on-year decline of 56.30% [1] - The basic earnings per share were reported at 0.09 yuan [1]

Core Insights - The company reported a total revenue of 347 million yuan for the first half of 2025, representing a year-on-year decline of 12.23% [1] - The net profit attributable to shareholders was 37.08 million yuan, down 56.75% year-on-year, with basic earnings per share at 0.09 yuan [1] - The core business segment of gastrointestinal drugs saw revenue growth, while sales in sexual health and ophthalmic drugs declined [1] R&D and Product Development - R&D investment reached 48.64 million yuan in the first half of 2025, with significant progress in innovative drug development and key product industrialization [1] - The II phase clinical trial for CKBA ointment targeting vitiligo has completed data organization and unblinding, showing positive efficacy and safety in non-segmental vitiligo patients [1] - The application for breakthrough therapy status for CKBA has been submitted to CDE, with preparations for the III phase clinical trial underway [1] Product Pipeline and Market Strategy - The application for the II/III phase seamless adaptive clinical trial of CKBA cream for rosacea has been officially accepted, confirming its development potential in the autoimmune field [2] - The domestic production registration application for Hewei Zhengchang Wan has been accepted, with production line modifications completed for rapid commercialization upon approval [2] - New gastrointestinal products, including Compound Sodium Sulfate Tablets, have completed clinical research and received market acceptance, enhancing the product matrix [2] Strategic Focus - The year 2025 is identified as a critical year for the company's dual strategy of innovation and brand promotion [3] - Increased investment in brand promotion aims to establish a solid foundation for the commercialization of core potential products like Hewei Zhengchang Wan and others [3] - The company targets significant sales growth in its three core segments: gastrointestinal, ophthalmic, and sexual health over the next 3-5 years [3]